Pre-made Nimotuzumab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody, Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nimotuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nimotuzumab (h-R3,[2] BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.
| Products Name (INN Index) | Pre-Made Nimotuzumab biosimilar, Whole mAb, Anti-EGFR Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2 therapeutic antibody |
|---|---|
| INN Name | Nimotuzumab |
| Target | EGFR |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 3gkw:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | Biocon Biopharmaceuticals,Biotech Pharmaceutical,Center of Molecular Immunology,CIMYM,Daiichi Sankyo Inc,Eurofarma,Gilead Sciences,Innogene Kalbiotech,InnoMab,Kuhnil Pharmaceutical Company,Laboratori |
| Conditions Approved | Anaplastic astrocytoma,Brain cancer,Glioblastoma,Glioma,Head and neck cancer,Nasopharyngeal cancer,Oesophageal cancer |
| Conditions Active | Cervical cancer,Non-small cell lung cancer,Pancreatic cancer,Breast cancer,Colorectal cancer |
| Conditions Discontinued | Gastric cancer,Polycystic kidney disease,Prostrate cancer,Brain metastases,Squamous cell cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR |
| Package |
